2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers

Author

Suárez-Calvet, Marc

Kleinberger, Gernot

Araque Caballero, Miguel Ángel

Brendel, Matthias

Rominger, Axel

Alcolea, Daniel

Fortea, Juan

Lleó, Alberto

Blesa, Rafael

Gispert, Juan Domingo

Sanchez-Valle, Raquel

Antonell, Anna

Rami Gonzalez, Lorena

Molinuevo, José Luis

Brosseron, Frederic

Traschütz, Andreas

Heneka, Michael

Struyfs, Hanne

Engelborghs, Sebastiaan

Sleegers, Kristel

Van Broeckhoven, Christine

Zetterberg, Henrik

Nellgård, Bengt

Blennow, Kaj

Crispin, Alexander

Ewers, Michael

Haass, Christian

Universitat Autònoma de Barcelona

Publication date

2016

Abstract

2 is an innate immune receptor expressed on the surface of microglia. Loss-of-function mutations of 2 are associated with increased risk of Alzheimer's disease (). 2 is a type-1 protein with an ectodomain that is proteolytically cleaved and released into the extracellular space as a soluble variant (2), which can be measured in the cerebrospinal fluid (). In this cross-sectional multicenter study, we investigated whether levels of 2 are changed during the clinical course of , and in cognitively normal individuals with suspected non- pathology (). 2 levels were higher in mild cognitive impairment due to than in all other groups and controls. individuals also had significantly increased 2 compared to controls. Moreover, increased 2 levels were associated with higher total tau and phospho-tau, which are markers of neuronal degeneration and tau pathology. Our data demonstrate that 2 levels are increased in the early symptomatic phase of , probably reflecting a corresponding change of the microglia activation status in response to neuronal degeneration.

Document Type

Article

Language

English

Subjects and keywords

Alzheimer's disease; Biomarkers; Microglia; Neurodegeneration; TREM2; Biomarkers & Diagnostic Imaging; Neuroscience

Publisher

 

Related items

European Commission P7-2007-2013

EMBO Molecular Medicine ; Vol. 8 (march 2016), p. 466-476

Rights

open access

Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.

https://creativecommons.org/licenses/by/4.0/

This item appears in the following Collection(s)